File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Central administration of C-x-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice

TitleCentral administration of C-x-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice
Authors
Issue Date2014
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
Citation
PLoS One, 2014, v. 9 n. 8, p. e104860 How to Cite?
AbstractAim To explore the roles of C-X-C chemokine receptor type 4 (CXCR4) in spinal processing of neuropathic pain at the central nervous system (CNS). Methods Peripheral neuropathic pain (PNP) induced by partial sciatic nerve ligation (pSNL) model was assessed in mice. Effects of a single intrathecal (central) administration of AMD3100 (intrathecal AMD3100), a CXCR4 antagonist, on pain behavior and pain-related spinal pathways and molecules in the L3-L5 spinal cord segment was studied compare to saline treatment. Results Rotarod test showed that intrathecal AMD3100 did not impair mice motor function. In pSNL-induced mice, intrathecal AMD3100 delayed the development of mechanical allodynia and reversed the established mechanical allodynia in a dose-dependent way. Moreover, intrathecal AMD3100 downregulated the activation of JNK1 and p38 pathways and the protein expression of p65 as assessed by western blotting. Real-time PCR test also demonstrated that substance P mRNA was decreased, while adrenomedullin and intercellular adhesion molecule mRNA was increased following AMD3100 treatment. Conclusion Our results suggest that central (spinal) CXCR4 is involved in the development and maintenance of PNP and the regulation of multiple spinal molecular events under pain condition, implicating that CXCR4 would potentially be a therapeutic target for chronic neuropathic pain.
Persistent Identifierhttp://hdl.handle.net/10722/202479
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorLuo, Xen_US
dc.contributor.authorTai, WLen_US
dc.contributor.authorSun, LTen_US
dc.contributor.authorQiu, Qen_US
dc.contributor.authorXia, Zen_US
dc.contributor.authorChung, SKen_US
dc.contributor.authorCheung, CWen_US
dc.date.accessioned2014-09-19T07:59:35Z-
dc.date.available2014-09-19T07:59:35Z-
dc.date.issued2014en_US
dc.date.submittedPMC4132096-
dc.identifier.citationPLoS One, 2014, v. 9 n. 8, p. e104860en_US
dc.identifier.urihttp://hdl.handle.net/10722/202479-
dc.description.abstractAim To explore the roles of C-X-C chemokine receptor type 4 (CXCR4) in spinal processing of neuropathic pain at the central nervous system (CNS). Methods Peripheral neuropathic pain (PNP) induced by partial sciatic nerve ligation (pSNL) model was assessed in mice. Effects of a single intrathecal (central) administration of AMD3100 (intrathecal AMD3100), a CXCR4 antagonist, on pain behavior and pain-related spinal pathways and molecules in the L3-L5 spinal cord segment was studied compare to saline treatment. Results Rotarod test showed that intrathecal AMD3100 did not impair mice motor function. In pSNL-induced mice, intrathecal AMD3100 delayed the development of mechanical allodynia and reversed the established mechanical allodynia in a dose-dependent way. Moreover, intrathecal AMD3100 downregulated the activation of JNK1 and p38 pathways and the protein expression of p65 as assessed by western blotting. Real-time PCR test also demonstrated that substance P mRNA was decreased, while adrenomedullin and intercellular adhesion molecule mRNA was increased following AMD3100 treatment. Conclusion Our results suggest that central (spinal) CXCR4 is involved in the development and maintenance of PNP and the regulation of multiple spinal molecular events under pain condition, implicating that CXCR4 would potentially be a therapeutic target for chronic neuropathic pain.-
dc.languageengen_US
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action-
dc.relation.ispartofPLoS Oneen_US
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleCentral administration of C-x-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in miceen_US
dc.typeArticleen_US
dc.identifier.emailSun, LT: ltsun@hku.hken_US
dc.identifier.emailXia, Z: zyxia@hkucc.hku.hken_US
dc.identifier.emailChung, SK: skchung@hkucc.hku.hken_US
dc.identifier.emailCheung, CW: cheucw@hku.hken_US
dc.identifier.authorityXia, Z=rp00532en_US
dc.identifier.authorityChung, SK=rp00381en_US
dc.identifier.authorityCheung, CW=rp00244en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1371/journal.pone.0104860-
dc.identifier.pmid25119456-
dc.identifier.pmcidPMC4132096-
dc.identifier.hkuros235551en_US
dc.identifier.volume9en_US
dc.identifier.issue8en_US
dc.identifier.spagee104860en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats